See more : Orient Paper & Industries Limited (ORIENTPPR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Myomo, Inc. (MYO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myomo, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Ability Inc. (ABIL-L.TA) Income Statement Analysis – Financial Results
- Two Rivers Financial Group, Inc. (TRVR) Income Statement Analysis – Financial Results
- Vincerx Pharma, Inc. (VINCW) Income Statement Analysis – Financial Results
- Winning Health Technology Group Co., Ltd. (300253.SZ) Income Statement Analysis – Financial Results
- Jiangxi Sanxin Medtec Co.,Ltd. (300453.SZ) Income Statement Analysis – Financial Results
Myomo, Inc. (MYO)
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.10M | 689.67K | 913.25K |
| Cost of Revenue | 6.06M | 5.30M | 3.54M | 2.60M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| Gross Profit | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Profit Ratio | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.20% | 67.59% | 74.42% | 64.56% | 76.83% |
| Research & Development | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| General & Administrative | 16.02M | 14.37M | 14.44M | 12.98M | 11.25M | 10.41M | 5.85M | 2.93M | 3.10M | 2.85M |
| Selling & Marketing | 3.22M | 4.07M | 3.59M | 841.30K | 301.70K | 136.30K | 31.00K | 41.60K | 119.70K | 14.30K |
| SG&A | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| Other Expenses | 0.00 | -1.10K | -16.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.60M | 4.10M | 3.98M | 3.44M |
| Cost & Expenses | 27.47M | 26.23M | 24.12M | 18.09M | 14.63M | 12.97M | 8.11M | 4.38M | 4.22M | 3.65M |
| Interest Income | 410.27K | 88.73K | 1.61K | 474.71K | 112.49K | 0.00 | 0.00 | 0.00 | 196.06K | 178.86K |
| Interest Expense | 0.00 | 88.73K | 15.34K | 474.71K | 113.63K | 358.92K | 358.92K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.42K | 7.73K | 5.31K | 6.16K |
| EBITDA | -7.71M | -10.13M | -9.93M | -11.24M | -10.70M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Ratio | -40.09% | -65.12% | -71.68% | -137.06% | -283.88% | -429.40% | -86.36% | -296.14% | -511.58% | -299.50% |
| Operating Income | -8.23M | -10.67M | -10.27M | -10.50M | -10.80M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Income Ratio | -42.78% | -68.61% | -74.10% | -138.50% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Total Other Income/Expenses | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Income Before Tax | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.10M | -3.62M | -3.73M | -2.92M |
| Income Before Tax Ratio | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax Expense | 156.00K | 69.94K | 88.93K | 474.71K | -81.99K | -247.95K | 5.57M | 342.02K | 752.61K | 607.62K |
| Net Income | -8.15M | -10.72M | -10.37M | -12.04M | -10.63M | -10.32M | -12.10M | -3.62M | -4.48M | -3.53M |
| Net Income Ratio | -42.34% | -68.92% | -74.86% | -158.75% | -277.01% | -422.11% | -776.04% | -327.84% | -649.90% | -386.29% |
| EPS | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Diluted | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| Weighted Avg Shares Out | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Weighted Avg Shares Out (Dil) | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
Myomo Reports Fourth Quarter and Full Year 2023 Financial Results
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced financial results for the three months and year ended December...
CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro®
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that on February 29, 2024, the Centers for Medicare &...
Myomo to Report Fourth Quarter Financial Results on March 7, 2024
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the fourth quarter...
Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has closed its previously announced registered direct offering...
Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it has entered into securities purchase agreements with certain...
Myomo Reports Preliminary Fourth Quarter Revenue and Backlog
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced preliminary revenue and operating metrics for the fourth quarter of...
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
If you are looking for stocks that are well positioned to maintain their recent uptrend, Myomo, Inc. (MYO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
7 Stock Winners That Are Up 1,000% or More in 2023
As you may already suspect, there are not a lot of stocks up 1000% year-to-date, but several stocks trading on major exchanges are up 1000% from their lows set earlier in the calendar year. There are also a few fairly-liquid...
Myomo: Market Severely Undervaluing Opportunity
Market undervalues MYO stock due to poor understanding of CMS process. MYO is able to generate revenues in excess of $100mm/yr. MYO valuation gap will close before February 2024, when the final CMS price is published.
3 Hot Penny Stocks to Buy in Q4 for Promising Potential
Penny stocks are typically companies that are trading below $5 per share. These companies are ones that can be risky to invest in.
Source: https://incomestatements.info
Category: Stock Reports